Results 251 to 260 of about 4,508,328 (306)
Some of the next articles are maybe not open access.
Molecular pharmacology of niaprazine
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 19881. The pharmacological profile of niaprazine was investigated using in vitro ligand binding techniques. 2. Niaprazine exhibits a low affinity for the vesicular monoamine transporter and for D2, alpha 2, beta, H1 and muscarinic cholinergic receptors. Niaprazine, particularly the (+)stereoisomer, has a higher affinity for alpha 1 (Ki = 77 nM) and 5-HT2 ...
D, Scherman +6 more
openaire +2 more sources
Molecular Pharmacology of Phytocannabinoids
2017Cannabis sativa has been used for recreational, therapeutic and other uses for thousands of years. The plant contains more than 120 C21 terpenophenolic constituents named phytocannabinoids. The Δ9-tetrahydrocannabinol type class of phytocannabinoids comprises the largest proportion of the phytocannabinoid content.
Sarah E, Turner +3 more
openaire +2 more sources
Molecular Pharmacology of the Calcitonin Receptor
Receptors and Channels, 2002The peptide hormone calcitonin is widely used therapeutically in the treatment of bone disorders such as Paget's disease, osteoporosis, and the hypercalcemia of some malignancies. However, emerging evidence suggests the actions of calcitonin via its G protein-coupled receptor, the calcitonin receptor, may not be limited to bone.
Purdue, BW, Tilakaratne, N, Sexton, PM
openaire +5 more sources
The Molecular Pharmacology of SERMs
Trends in Endocrinology & Metabolism, 1999Estrogen-containing medicines have been used successfully for the past 50 years for the treatment of conditions associated with menopause. Although initially considered a reproductive hormone, millions of years of clinical exposure to estrogen(s) have indicated that its influence extends to a variety of target tissues not generally considered to be ...
openaire +2 more sources
Molecular Pharmacology of Hallucinogens
1968There is as yet no satisfactory biological explanation for any of the major psychoses. However, the gap in knowledge is diminishing, and already there is a flourishing exchange of ideas and correlations between clinician and researcher. In fact, there is an ever increasing number of practising psychiatrists with active biological research interests.
V S, Johnston, R J, Bradley
openaire +2 more sources
Molecular Pharmacology of Nitrosoureas
1981The development of a wide range of aliphatic nitrosamides has followed the original observation that l-methyl-l-nitroso-3-nitrosoguanidine had reproducible antitumor activity against murine L1210 leukemia [7]. The resultant synthesis of new N-nitroso containing compounds has produced two general classes of drug, the methyl and chloroethyl nitrosoureas.
K D, Tew, M E, Smulson, P S, Schein
openaire +2 more sources
Molecular Pharmacology of Gonadotropins
Endocrine, 2005Gonadotropins have been studied in biological systems for decades and many of their properties are well defined. These include pharmacological properties such as affinity, stability, and pharmacokinetics also used to characterize drugs. Technologies applied to research on gonadotropins have led to the creation of hormone analogs with alterations to one
openaire +2 more sources
Modeling and Simulation in Molecular Pharmacology
1998A stochastic simulation program of drug-receptor interaction is presented. The user can select a set of conditions concerning the processes of response release (type of cellular response, drug distribution and metabolism etc.) and the program plots a family of dose-response curves.
George I. Mihalas +3 more
openaire +2 more sources
Molecular pharmacology of the opioid receptors
Pharmacology & Therapeutics, 1995Opioid receptors are the primary sites of actions of opiates and endogenous opioid peptides, which have a wide variety of pharmacological and physiological effects. The opioid receptors are classified into at least three subtypes, mu, delta, and kappa, and their cDNAs have been cloned.
M, Satoh, M, Minami
openaire +2 more sources
Molecular pharmacology of somatostatin receptors
Naunyn-Schmiedeberg's Archives of Pharmacology, 1994The neuropeptide somatostatin (SRIF) is widely expressed in the brain and in the periphery in two main forms, SRIF-14 and SRIF-28. Similarly, the presence of SRIF receptors throughout the whole body has been reported. SRIF produces a variety of effects including modulation of hormone release (e.g.
D, Hoyer, H, Lübbert, C, Bruns
openaire +2 more sources

